デフォルト表紙
市場調査レポート
商品コード
1386998

放射性医薬品セラノスティクス市場レポート:2030年までの動向、予測、競合分析

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

放射性医薬品セラノスティクス市場レポート:2030年までの動向、予測、競合分析
出版日: 2023年10月16日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

放射性医薬品セラノスティクスの動向と予測

放射性医薬品セラノスティクスの世界市場は、2024年から2030年までのCAGRが11.2%で、2030年までに推定39億米ドルに達すると予想されます。この市場の主な促進要因は、がん罹患率の増加と心血管疾患治療への応用の増加です。放射性医薬品セラノスティクスの世界市場の将来は、病院、画像診断センター、学術・研究機関市場に機会があり、有望視されています。

放射性医薬品セラノスティクス市場の洞察

Lucintelは、PETトレーサーが予測期間中に最も高い成長を遂げると予測しています。

この市場において、病院は技術的に高度なシステムが利用可能であり、病院数が増加しているため、最大のセグメントであり続けると思われます。

北米は、慢性疾患の増加、放射性医薬品やペットスキャナーの入手が容易であることから、予測期間中に最も高い成長が見込まれます。

本レポートは以下の11の主要な質問に答えている:

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か?
  • Q.2.今後成長が加速するセグメントとその理由は?
  • Q.3.今後成長が加速すると思われる地域とその理由は?
  • Q.4.市場力学に影響を与える主な要因は何か?市場における主な課題とビジネスリスクは?
  • Q.5.この市場におけるビジネスリスクと競合の脅威は?
  • Q.6.この市場における新たな動向とその理由は?
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか?
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は?
  • Q.9.この市場における主要企業は?主要企業は事業成長のためにどのような戦略的取り組みを進めているのか?
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか?
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか?

目次

第1章 エグゼクティブサマリー

第2章 世界の放射性医薬品セラノスティクス市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界の放射性医薬品セラノスティクス市場動向(2018-2023)と予測(2024-2030)
  • 製品タイプ別の世界の放射性医薬品セラノスティクス市場
    • アルファエミッター
    • ベータエミッター
    • PETトレーサー
  • 由来別の世界の放射性医薬品セラノスティクス市場
    • 原子炉
    • サイクロトロン
  • 適応症別の世界の放射性医薬品セラノスティクス市場
    • オンコロジー
    • 心臓病学
    • 神経内科
    • その他
  • 最終用途別の世界の放射性医薬品セラノスティクス市場
    • 病院
    • 画像診断センター
    • 学術研究機関
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の放射性医薬品セラノスティクス市場
  • 北米の放射性医薬品セラノスティクス市場
  • 欧州の放射性医薬品セラノスティクス市場
  • アジア太平洋の放射性医薬品セラノスティクス市場
  • その他地域放射性医薬品セラノスティクス市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 製品タイプ別の世界の放射性医薬品セラノスティクス市場の成長機会
    • 由来別の世界の放射性医薬品セラノスティクス市場の成長機会
    • 適応症別の世界の放射性医薬品セラノスティクス市場の成長機会
    • 最終用途別の世界の放射性医薬品セラノスティクス市場の成長機会
    • 地域別の世界の放射性医薬品セラノスティクス市場の成長機会
  • 世界の放射性医薬品セラノスティクス市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の放射性医薬品セラノスティクス市場の能力拡大
    • 世界の放射性医薬品セラノスティクス市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Bayer
  • GE HealthCare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • NuView Life Sciences
目次

Radiopharmaceutical Theranostics Trends and Forecast

The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

A more than 150-page report is developed to help in your business decisions.

Radiopharmaceutical Theranostics by Segment

The study includes a forecast for the global radiopharmaceutical theranostics by product type, source, indication, end use, and region.

Radiopharmaceutical Theranostics Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Alpha Emitters
  • Beta Emitters
  • PET Tracers

Radiopharmaceutical Theranostics Market by Source [Shipment Analysis by Value from 2018 to 2030]:

  • Nuclear Reactors
  • Cyclotrons

Radiopharmaceutical Theranostics Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Cardiology
  • Neurology
  • Others

Radiopharmaceutical Theranostics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes
  • Others

Radiopharmaceutical Theranostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Radiopharmaceutical Theranostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiopharmaceutical theranostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiopharmaceutical theranostics companies profiled in this report include-

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Radiopharmaceutical Theranostics Market Insights

Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Within this market, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.

North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Features of the Global Radiopharmaceutical Theranostics Market

Market Size Estimates: Radiopharmaceutical theranostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiopharmaceutical theranostics market size by various segments, such as by product type, source, indication, end use, and region in terms of value ($B).

Regional Analysis: Radiopharmaceutical theranostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, sources, indications, end uses, and regions for the radiopharmaceutical theranostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiopharmaceutical theranostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the radiopharmaceutical theranostics market size?

Answer: The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030.

Q.2 What is the growth forecast for radiopharmaceutical theranostics market?

Answer: The global radiopharmaceutical theranostics market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the radiopharmaceutical theranostics market?

Answer: The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Q4. What are the major segments for radiopharmaceutical theranostics market?

Answer: The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets.

Q5. Who are the key radiopharmaceutical theranostics market companies?

Answer: Some of the key radiopharmaceutical theranostics companies are as follows:

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Q6. Which radiopharmaceutical theranostics market segment will be the largest in future?

Answer: Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Q7. In radiopharmaceutical theranostics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radiopharmaceutical theranostics market by product type (alpha emitters, beta emitters, and PET tracers), source (nuclear reactors and cyclotrons), indication (oncology, cardiology, neurology, and others), end use (hospitals, diagnostic imaging centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiopharmaceutical Theranostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radiopharmaceutical Theranostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radiopharmaceutical Theranostics Market by Product Type
    • 3.3.1: Alpha Emitters
    • 3.3.2: Beta Emitters
    • 3.3.3: PET Tracers
  • 3.4: Global Radiopharmaceutical Theranostics Market by Source
    • 3.4.1: Nuclear Reactors
    • 3.4.2: Cyclotrons
  • 3.5: Global Radiopharmaceutical Theranostics Market by Indication
    • 3.5.1: Oncology
    • 3.5.2: Cardiology
    • 3.5.3: Neurology
    • 3.5.4: Others
  • 3.6: Global Radiopharmaceutical Theranostics Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Diagnostic Imaging Centers
    • 3.6.3: Academic & Research Institutes
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radiopharmaceutical Theranostics Market by Region
  • 4.2: North American Radiopharmaceutical Theranostics Market
    • 4.2.2: North American Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.3: European Radiopharmaceutical Theranostics Market
    • 4.3.1: European Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.3.2: European Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.4: APAC Radiopharmaceutical Theranostics Market
    • 4.4.1: APAC Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.4.2: APAC Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.5: ROW Radiopharmaceutical Theranostics Market
    • 4.5.1: ROW Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.5.2: ROW Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Source
    • 6.1.3: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Indication
    • 6.1.4: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by End Use
    • 6.1.5: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Region
  • 6.2: Emerging Trends in the Global Radiopharmaceutical Theranostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radiopharmaceutical Theranostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiopharmaceutical Theranostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: GE HealthCare Technologies
  • 7.3: Curium
  • 7.4: Lantheus Medical Imaging
  • 7.5: Telix Pharmaceuticals
  • 7.6: Cardinal Health
  • 7.7: Advanced Accelerator Applications
  • 7.8: Jubilant Radiopharma
  • 7.9: Theragnostics
  • 7.10: NuView Life Sciences